Kinesin spindle protein SiRNA slows tumor progression

Journal of Cellular Physiology

Volumn 228, Issue 1, 2013, Pages 58-64

  Marra, Emanuele ^a,b   Palombo, Fabio ^c   Ciliberto, Gennaro ^d   Aurisicchio, Luigi ^a,b  

^a Takis srl   (Italy)

^b Grande Ospedale Metropolitano   (Italy)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

KINESIN; KINESIN SPINDLE PROTEIN; LUCIFERASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL PERMEABILIZATION; CENTROSOME; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; FEASIBILITY STUDY; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; INTRATUMOR ELECTROTRANSFER OF RNA THERAPEUTICS; MALE; MELANOMA; MICROTUBULE; MITOSIS; MITOSIS SPINDLE; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN FAMILY; RNA INTERFERENCE; TECHNOLOGY;

ANIMALS; CELL LINE, TUMOR; ELECTROPORATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GREEN FLUORESCENT PROTEINS; HUMANS; KINESIN; MALE; MELANOMA; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; OVARIAN NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84867152057     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24103     Document Type: Article

References (38)

1. Andrè F, Mir LM. 2004. DNA electrotransfer: Its principles and an updated review of its therapeutic applications. Gene Ther 11: S33-S42.
2. Andrè FM, Mir LM. 2010. Nucleic acids electrotransfer in vivo: Mechanisms and practical aspects. Curr Gene Ther 10: 267-280.
3. Aurisicchio L, Mennuni C, Giannetti P, Calvaruso F, Nuzzo M, Cipriani B, Palombo F, Monaci P, Ciliberto G, La Monica N. 2007. Immunogenicity and safety of a DNA prime/adenovirus boost vaccine against rhesus CEA in nonhuman primates. Int J Cancer 120: 2290-2300.
4. Aurisicchio L, Ciliberto G. 2011. Emerging cancer vaccines: The promise of genetic vectors. Cancers 3: 3687-3713.
5. Blangy A, Lane HA, d'Herin P, Harper M, Kress M, Nigg EA. 1995. Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell 83: 1159-1169.
6. Bodles-Bakhop AM, Heller R, Draghia-Akli R. 2009. Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: Current clinical developments. Mol Ther 17: 585-592.
7. Cappelletti M, Zampaglione I, Rizzuto G, Ciliberto G, La Monica N, Fattori E. 2003. Gene electro-transfer improves transduction by modifying the fate of intramuscular plasmid DNA. J Gene Med 5: 324-332.
8. Cox CD, Coleman PJ, Breslin MJ, Whitman DB, Garbaccio RM, Fraley ME, Buser CA, Walsh ES, Hamilton K, Schaber MD, Lobell RB Tao W, Davide JP, Diehl RE, Abrams MT, South VJ, Huber HE, Torrent M, Prueksaritanont T, Li C, Slaughter DE, Mahan E, Fernandez-Metzler C, Yan Y, Kuo LC, Kohl NE, Hartman GD. 2008. Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2, 5-difluorophenyl)-n-[(3R, 4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2, 5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancer. J Med Chem 51: 4239-4252.
9. Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, Heller R. 2008. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 26: 5896-5903.
10. Dassie JP, Liu XY, Thomas GS, Whitaker RM, Thiel KW, Stockdale KR, Meyerholz DK, McCaffrey AP, McNamara JO II, Giangrande PH. 2009. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 27: 839-849.
11. Davis ME, Zuckerman JE, Choi CHJ, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A. 2010. Evidence of RNAi in humans from systematically administered siRNA via targeted nanoparticles. Nature 464: 1067-1071.
12. Dharmapuri S, Peruzzi D, Aurisicchio L. 2009a. Engineered adenovirus serotypes for overcoming anti-vector immunity. Expert Opin Biol Ther 9: 1279-1287.
13. Dharmapuri S, Aurisicchio L, Biondo A, Welsh N, Ciliberto G, La Monica N. 2009b. Anti-apoptotic siRNA as potent adjuvant of DNA vaccination in a mouse mammary tumor model. Hum Gene Ther 20: 589-597.
14. Dharmapuri S, Peruzzi D, Marra E, Palombo F, Bett AJ, Bartz SR, Yong M, Ciliberto G, La Monica N, Buser CA, Toniatti C, Aurisicchio L. 2011. Intra-tumor RNA interference of cell cycle genes slows down tumor progression. Gene Ther 18: 727-733.
15. Gaglio T, Saredi A, Bingham JB, Hasbani MJ, Gill SR, Schroer TA, Compton DA. 1996. Opposing motor activities are required for the organization of the mammalian mitotic spindle pole. J Cell Biol 135: 399-414.
16. Heller LC, Heller R. 2010. Electroporation gene therapy preclinical and clinical trials for melanoma. Curr Gene Ther 10: 312-317.
17. Kapoor TM, Mayer TU, Coughlin ML, Mitchison TJ. 2000. Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin. J Cell Biol 150: 975-988.
18. Kim SI, Shin D, Choi TH, Lee JC, Cheon GJ, Kim KY, Park M, Kim M. 2007. Systemic and specific delivery of small interfering RNAs to the liver mediated by apolipoprotein A-I. Mol Ther 15: 1145-1152.
19. Knight SD, Parrish CA. 2008. Recent progress in the identification and clinical evaluation of inhibitors of the mitotic kinesin KSP. Curr Top Med Chem 8: 888-904.
20. Lohr F, Lo DY, Zaharoff DA, Hu K, Zhang X, Li Y, Zhao Y, Dewhirst MW, Yuan F, Li CY. 2001. Effective tumor therapy with plasmid-encoded cytokines combined with in vivo electroporation. Cancer Res 61: 3281-3284.
21. Low L, Mander A, McCann K, Dearnaley D, Tjelle T, Mathiesen I, Stevenson F, Ottensmeier CH. 2009. DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum Gene Ther 20: 1269-1278.
22. Lucas ML, Heller L, Coppola D, Heller R. 2002. IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol Ther 5: 668-675.
23. Nakai N, Kishida T, Shin-Ya M, Imanishi J, Ueda Y, Kishimoto S, Mazda O. 2007. Therapeutic RNA interference of malignant melanoma by electrotransfer of small interfering RNA targeting Mitf. Gene Ther 14: 357-365.
24. Paganin-Gioanni A, Bellard E, Escoffre JM, Rols MP, Teissié J, Golzio M. 2011. Direct visualization at the single-cell level of siRNA electrotransfer into cancer cells. Proc Natl Acad Sci USA 108: 10443-10447.
25. Peruzzi D, Mesiti G, Ciliberto G, La Monica N, Aurisicchio L. 2010a. Telomerase and HER-2/neu as targets of genetic cancer vaccines in dogs. Vaccine 28: 1201-1208.
26. Peruzzi D, Gavazza A, Mesiti G, Lubas G, Scarselli E, Conforti A, Bendtsen C, Ciliberto G, La Monica N, Aurisicchio L. 2010b. A vaccine targeting telomerase enhances survival of dogs affected by B-cell lymphoma. Mol Ther 18: 1559-1567.
27. Reinhold U. 2011. Electrochemotherapy for primary skin cancer and skin metastasis related to other malignancies. Anticancer Drugs 22: 711-718.
28. Rickert KW, Schaber M, Torrent M, Neilson LA, Tasber ES, Garbaccio R, Coleman PJ, Harvey D, Zhang Y, Yang Y, Marshall G, Lee L, Walsh ES, Hamilton K, Buser CA. 2008. Discovery and biochemical characterization of selective ATP competitive inhibitors of the human mitotic kinesin KSP. Arch Biochem Biophys 469: 220-231.
29. Rozema DB, Lewis DL, Wakefield DH, Wong SC, Klein JJ, Roesch PL, Bertin SL, Reppen TW, Chu Q, Blokhin AV, Hagstrom JE, Wolff JA. 2007. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci USA 104: 12982-12987.
30. Sato A, Takagi M, Shimamoto A, Kawakami S, Hashida M. 2007. Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice. Biomaterials 28: 1434-1442.
31. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, John M, Kesavan V, Lavine G, Pandey RK, Racie T, Rajeev KG, Röhl I, Toudjarska I, Wang G, Wuschko S, Bumcrot D, Koteliansky V, Limmer S, Manoharan M, Vornlocher HP. 2004. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432: 173-178.
32. Takei Y, Nemoto T, Mu P, Fujishima T, Ishimoto T, Hayakawa Y, Yuzawa Y, Matsuo S, Muramatsu T, Kadomatsu K. 2008. In vivo silencing of a molecular target by short interfering RNA electroporation: Tumor vascularization correlates to delivery efficiency. Mol Cancer Ther 7: 211-221.
33. Tao W, South VJ, Zhang Y, Davide JP, Farrell L, Kohl NE, Sepp-Lorenzino L, Lobell RB. 2005. Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell 8: 49-59.
34. Wu SY, McMillan NA. 2009. Lipidic systems for in vivo siRNA delivery. AAPS J 11: 639-652.
35. Yuan X, Naguib S, Wu Z. 2011. Recent advances of siRNA delivery by nanoparticles. Expert Opin Drug Deliv 8: 521-536.
36. Zamore PD, Tuschl T, Sharp PA, Bartel DP. 2000. RNAi: Double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101: 25-33.
37. Zhang Y, Xu W. 2008. Progress on kinesin spindle protein inhibitors as anti-cancer agents. Anticancer Agents Med Chem 8: 698-704.
38. Zhou J, Li H, Li S, Zaia J, Rossi JJ. 2008. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther 16: 1481-1489.